Advertisement

Neutrophil-to-Lymphocyte Ratio Predicts Cancer Outcome in Locally Advanced Clear Renal Cell Carcinoma

Published:November 22, 2021DOI:https://doi.org/10.1016/j.clgc.2021.10.009

      Abstract

      Background

      To evaluate the association of neutrophil-to-lymphocyte ratio (NLR) with recurrence-free survival (RFS) and overall survival (OS) in patients with locally advanced nonmetastatic clear cell renal cell carcinoma (ccRCC) undergoing radical nephrectomy.

      Material and Methods

      We retrospectively identified 880 nephrectomies performed between January 2009 and December 2016 in a single center, reviewed data from 478 radical nephrectomies for kidney tumors and identified 187 patients with locally advanced nonmetastatic ccRCC (pT3-T4 N0M0). NLR was obtained preoperatively and calculated by dividing absolute neutrophil count by absolute lymphocyte count. OS and RFS were evaluated by the Kaplan–Meier method. Cox proportional-hazards regression models were used to evaluate predictors of RFS and OS.

      Results

      Among 187 patients with ccRCC (mean age 63.4 ± 11.5 years; 118 [63.1%] male), the median follow-up was 48.7 months. On univariate analysis, in patients with Fuhrman nuclear grade of differentiation 3-4, the median time to recurrence was significantly shorter with NLR ≥ 4 than < 4 (24 vs. 55 months, P = .045). On multivariable analysis adjusted for NLR ≥ 4, among all variables analyzed (NLR, microvascular invasion, sarcomatoid differentiation, tumor size and body mass index), only nuclear grade of differentiation was an independent predictor of recurrence (hazard ratio 2.18; 95% confidence interval 1.07-4.92, P = .03). The 3-year OS had no statistically significant difference between patients with NLR ≥ 4 or < 4.

      Conclusion

      For patients with locally advanced, nonmetastatic ccRCC, RFS was reduced with high nuclear grade of differentiation and high preoperative NLR. These findings suggest an association between higher NLR and worse outcomes in locally advanced ccRCC.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel RL
        • Miller KD
        • Jemal A.
        Cancer statistics, 2018.
        CA Cancer J Clin. 2018; 68: 7-30
        • Zisman A
        • Pantuck AJ
        • Wieder J
        • et al.
        Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carci - noma.
        J Clin Oncol. 2002; 20: 4559-4566
        • Eggener SE
        • Yossepowitch O
        • Pettus JA
        • Snyder ME
        • Motzer RJ
        • Russo P.
        Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence.
        J Clin Oncol. 2006; 24: 3101-3106
        • Frank I
        • Blute ML
        • Cheville JC
        • Lohse CM
        • Weaver AL
        • Zincke H.
        An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score.
        J Urol. 2002; 168: 40-2395
        • Sorbellini M
        • Kattan MW
        • Snyder ME
        • et al.
        A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma.
        J Urol. 2005; 173: 48-51
        • Lam JS
        • Klatte T
        • Kim HL
        • et al.
        Prognostic factors and selection for clinical studies of patients with kidney cancer.
        Crit Rev Oncol Hematol. 2008; 65: 62-253
        • Grivennikov SI
        • Greten FR
        • Karin M.
        Immunity, inflamation, and Cancer.
        Cell. 2010; 140 (10.12glia.23132): 883-899
        • Petrie HT
        • Klassen LW
        • Kay HD.
        Inhibition of human cytotoxic T lymphocyte activity in vitro by autologous peripheral blood granulocytes.
        J Immunol. 2021; 134: 230-234
        • Ishizuka M
        • Nagata H
        • Takagi K
        • Iwasaki Y
        • Kubota K.
        Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients with colorrectal cancer.
        Br J Cancer. 2013; 109: 401-407
        • Yamanaka T
        • Matsumoto S
        • Teramukai S
        • Ishiwata R
        • Nagai Y
        • Fukushima M.
        The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer.
        Oncology. 2007; 73: 215-220
        • Saroha S
        • Uzzo RG
        • Plimack ER
        • Ruth K
        • Saleem Al
        T Lymphopenia is an independent predictor of inferior outcome in clear cell renal carcinoma.
        J Urol. 2013; 189: 454-461
        • Nunno VD
        • Mollica V
        • Gatto L
        • et al.
        Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis.
        Immunotherapy. 2019; 11: 631-643
        • Vano YA
        • Oudard S
        • By MA
        • et al.
        Optimal cut-off for neutrophil-to-lymphocyte ratio: fact or fantasy? A prospective cohort study in metastatic cancer patients.
        PLoS One. 2018; 13e0195042
        • Coffelt GJ
        • Wellenstein MD
        • de Visser KE.
        Neutrophils in câncer: neutral no more.
        Nat Rev Cancer. 2016; 16: 431-446
        • Nozawa H
        • Chiu C
        • Hanahan D.
        Infiltrating neutrophils mediate the initial angiogenic switch in a mouse modelo f multistage carcinogenesis.
        Proc Natl Acad Sci USA. 2006; 103: 12493-12498
        • Gooden MH
        • de Book GH
        • Leffers N
        • Daemen T
        • Nijman HW.
        The prognostic influence of tumour-infiltrating lymphocytes in câncer: a systematic review with meta-analysis.
        Br J Cancer. 2011; 105: 93-103
        • Templeton AJ
        • Knox JJ
        • Lin X
        • et al.
        Change in neutrophil-to-lymphocyte ratio in response to targeted therapy for metastatic renal cell carcinoma as a prognosticator and biomarker of efficacy.
        Eur Urol. 2016; 70: 358-364
        • Templeton AJ
        • McNamara MG
        • Seruga B
        • et al.
        Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis.
        J Natl Cancer Inst. 2014; 106 (dju): 124
        • Frank I
        • Blute ML
        • Cheville HC
        • et al.
        Na outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score.
        J Urol. 2022; 168: 2395
        • Kattan MW
        • Reuter V
        • Motzer RH
        • et al.
        A post-operative prognostic nomogram for renal cell carcinoma.
        J Urol. 2001; 166: 63
        • Zisman A
        • Pantuck AJ
        • Wieder J
        • et al.
        Risck group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma.
        J Clin Oncol. 2002; 20: 4559
        • Cindolo L
        • de la TA
        • Messina G
        • et al.
        A preoperative clinical prognostic model for non-metastatic renal cell carcinoma.
        BJU Int. 2003; 92: 901
        • Yaycioglu O
        • Roberts WW
        • Chan T
        • et al.
        Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model.
        Urology. 2001; 58: 141
        • Ohno Y
        • Nakashima J
        • Ohnori M
        • Hatano T
        • Tachibana M.
        Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma.
        J Urol. 2010; 184: 873-878
        • Lucca I
        • de Martino M
        • Hofbauer SL
        • Zamani N
        • Shariat SF
        • Klatte T.
        Comparison of the prognostic value of pretreatment measurements os systemic inflammatory response in patients undergoing curative ressection of clear cell renal cell carcinoma.
        World J Urol. 2015; 33: 2045-2052
        • Grivas N
        • Kafarakis V
        • Tsimaris I
        • Raptis P
        • Hastazeris K
        • Stabropoulos NE.
        Clinco-pathological prognosis factors of renal cell carcinoma: a 15-years review from a single center in Greece.
        Urol Ann. 2014; 6: 116-121
        • Pichler M
        • Hutterer GC
        • Stoeckigt C
        • Chromecki TF
        • Stojakovic T
        • Golbeck S.
        Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic fator in a large European cohort of renal cell carcinoma patients.
        Br J Cancer. 2013; 108: 901-907
        • Wen RM
        • Zhang YJ
        • Ma S
        • et al.
        Preoperative neutrophil-to-lymphocyte ratio as a prognostic fator in patients with non-metastatic renal cell carcinoma.
        Asian Pac J Cancer Prev. 2015; 16: 3703-3708
        • Ohno Y
        • Nakashima J
        • Ohori M
        • Gondo T
        • Hatano T
        • Tachibana M.
        Followup of neutrophil-to-lymphocite ratio and recurrence of clear cell renal carcinoma.
        J Urol. 2012; 187: 411-417https://doi.org/10.1016/j.juro.2011.10.026